S&P Futures
4,082.25 +0.50 (+0.01%) Dow Futures
34,419.00 -10.00 (-0.03%) Nasdaq Futures
12,057.50 -5.25 (-0.04%) Russell 2000 Futures
1,883.40 -0.30 (-0.02%) Crude Oil
81.30 +0.08 (+0.10%) Gold
1,814.10 -1.10 (-0.06%)
NeoGenomics, Inc. (NEO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 11.21 |
| Open | 11.29 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 10.85 - 11.55 |
| 52 Week Range | 6.00 - 35.40 |
| Volume | |
| Avg. Volume | 1,252,640 |
| Market Cap | 1.411B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Feb 21, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.11 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NEO
Related Research
- NeoGenomics, Inc.NEO: Raising target price to $11.00NEOGENOMICS INC has an Investment Rating of HOLD; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of High.RatingFair ValueEconomic Moat2 days agoArgus Research
- ACCESSWIRE
RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, and its liquid biopsy-focused subsidiary, Inivata Limited ("Inivata") today announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, support the use of the RaDaR®Assay across all types of early breast cancer in both the adjuvant and surveillance settings.
- ACCESSWIRE
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)
NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers (EOC).Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq:IMGN), EOC patients will have access to the FOLR1 IHC CDx test (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to
- Motley Fool
Why Shares of NeoGenomics Jumped 53.9% This Week
Shares of NeoGenomics (NASDAQ: NEO) jumped 53.9% this week, according to data from S&P Global Market Intelligence. The cancer diagnostic company's stock closed last Friday at $7.31 a share and then opened on Monday at $7.41. It is in the midst of a turnaround plan, announced as Project Catalyst this past summer, which involves adopting automation into the company's lab processes.
